The Suppression Of Graft Versus Host Disease In Hematopoietic Stem Cell Transplantation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for the suppression of graft versus host disease in hematopoietic stem cell transplantation. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2039. Daily refresh.

1
Approved drugs
5
Active US patents
71/100
Avg vulnerability
—
Annual revenue covered

Originators in The Suppression Of Graft Versus Host Disease In Hematopoietic Stem Cell Transplantation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche Palo 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating the suppression of graft versus host disease in hematopoietic stem cell transplantation. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cellcept
MYCOPHENOLATE MOFETIL
 Roche Palo 5 71 — 2039-08-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12194143 Cellcept method of use 75 2039-08-16
12097285 Cellcept method of use 75 2039-08-16
12226526 Cellcept method of use 75 2039-08-16
11931455 Cellcept method of use 75 2039-08-16
12097284 Cellcept formulation 55 2039-08-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12097284 Cellcept formulation 55 2039-08-16
12194143 Cellcept method of use 75 2039-08-16
12097285 Cellcept method of use 75 2039-08-16
12226526 Cellcept method of use 75 2039-08-16
11931455 Cellcept method of use 75 2039-08-16

Related